诺和诺德中国业务大调整

动脉网
Nov 11

2025年11月11日文件显示,诺和诺德中国自2026年1月1日起实施重大业务重组:新兴事业部更名胰岛素事业部,聚焦创新胰岛素产品线;肥胖症与糖尿病事业部强化GLP-1核心地位,全面承接司美格鲁肽全场景业务,巩固糖尿病领域优势,冲击肥胖症市场领导地位;商务及零售事业部统筹基层医院覆盖等,成为双核心业务“终端推手”。这将是诺和诺德中国2025年战略动作收官之作,呼应全球转型需求。11月5日诺和诺德...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10